| Identification | Back Directory | [Name]
Pyrido[3,2-d]pyrimidine-2,4-diamine, 7-fluoro-N2-[1-(2-methyl-2-azaspiro[3.3]hept-6-yl)-1H-pyrazol-4-yl]-N4-(1-methylethyl)-6-(2-methyl-5-pyrimidinyl)- | [CAS]
2667681-85-6 | [Synonyms]
IRAK4-IN-15
Pyrido[3,2-d]pyrimidine-2,4-diamine, 7-fluoro-N2-[1-(2-methyl-2-azaspiro[3.3]hept-6-yl)-1H-pyrazol-4-yl]-N4-(1-methylethyl)-6-(2-methyl-5-pyrimidinyl)- | [Molecular Formula]
C25H29FN10 | [MOL File]
2667681-85-6.mol | [Molecular Weight]
488.56 |
| Hazard Information | Back Directory | [Uses]
IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC50 of 0.002 μM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. [1]. | [IC 50]
IRAK4: 0.002 μM (IC50) | [References]
[1] Degorce SL, et al. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. Bioorg Med Chem. 2020 Dec 1;28(23):115815. DOI:10.1016/j.bmc.2020.115815 |
|
|